FDA News Release: Published on November, 2022Type one diabetes mellitus (T1DM) is an autoimmune disease characterized by gradual destruction of beta cells in islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody, which have beneficial effects for T1DM patients.The U.S. Food and Drug Administration (FDA) has approved tepl...

COVID-19 Update:In light of the most recent information and data available, today, the FDA revised the authorizations for two monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and casirivimab and imdevimab – to limit their use to only when the patient is likely to have been infected with or exposed to a varian...